Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$951.19−8.22 (-0.86%)
Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –
Regeneron Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Regeneron Pharmaceuticals's enterprise value was $96.79B on Nov 11, 2026, against $79.48B a year earlier. Over the last 5 years it ranged from $49.58B to $127.70B, with a median of $77.29B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $96.79B | +23.2% |
| 2025 | Dec 31, 2025 | $78.56B | +5.9% |
| 2024 | Dec 31, 2024 | $74.18B | -19.4% |
| 2023 | Dec 29, 2023 | $92.06B | +20.0% |
| 2022 | Dec 30, 2022 | $76.72B | +14.8% |
| 2021 | Dec 31, 2021 | $66.81B | +22.2% |
| 2020 | Dec 31, 2020 | $54.65B | +35.9% |
| 2019 | Dec 31, 2019 | $40.22B | -1.4% |
| 2018 | Dec 31, 2018 | $40.77B | -3.4% |
| 2017 | Dec 29, 2017 | $42.21B | +2.9% |
| 2016 | Dec 30, 2016 | $41.03B | -33.3% |
| 2015 | Dec 31, 2015 | $61.50B | +39.2% |
| 2014 | Dec 31, 2014 | $44.20B | +38.8% |
| 2013 | Dec 31, 2013 | $31.85B | +100.5% |
| 2012 | Dec 31, 2012 | $15.89B | +233.3% |
| 2011 | Dec 30, 2011 | $4.77B | +121.8% |
| 2010 | Dec 31, 2010 | $2.15B | – |
See a number that looks wrong?